SNCAIP 抗体 (Internal Region)
-
- 抗原 See all SNCAIP 抗体
- SNCAIP (Synuclein, alpha Interacting Protein (SNCAIP))
-
抗原表位
- Internal Region
-
适用
- 人
-
宿主
- 兔
-
克隆类型
- 多克隆
-
标记
- This SNCAIP antibody is un-conjugated
-
应用范围
- Western Blotting (WB), Immunohistochemistry (IHC)
- 特异性
- Specific for Synphilin-1.
- 交叉反应
- 人
- 交叉反应 （详细）
- Other species not yet tested.
- 纯化方法
- IgG
- 免疫原
- A synthetic peptide from the internal region of human Synphilin-1 (Synphilin 1, alpha synuclein interacting protein) conjugated to an immunogenic carrier protein was used as the antigen.
- 亚型
- IgG
- Top Product
- Discover our top product SNCAIP Primary Antibody
-
anti-Synuclein, alpha Interacting Protein (SNCAIP) (AA 309-553) antibody
SNCAIP 适用: 人 ELISA, IHC, IF 宿主: 兔 Polyclonal unconjugated
anti-Synuclein, alpha Interacting Protein (SNCAIP) (AA 51-150) antibodySNCAIP 适用: 小鼠, 大鼠 WB, ELISA, IF (cc), IF (p), IHC (p), IHC (fro) 宿主: 兔 Polyclonal unconjugated
anti-Synuclein, alpha Interacting Protein (SNCAIP) (AA 206-309) antibodySNCAIP 适用: 人 WB, ELISA 宿主: 小鼠 Monoclonal 2A8 unconjugated
anti-Synuclein, alpha Interacting Protein (SNCAIP) (AA 1-603) antibodySNCAIP 适用: 人 WB 宿主: 小鼠 Polyclonal unconjugated
anti-Synuclein, alpha Interacting Protein (SNCAIP) (C-Term) antibodySNCAIP 适用: 人 WB, ELISA, IHC 宿主: 兔 Polyclonal unconjugated
anti-Synuclein, alpha Interacting Protein (SNCAIP) (C-Term) antibodySNCAIP 适用: 人, 小鼠 WB, ELISA, IHC 宿主: 兔 Polyclonal unconjugated
anti-Synuclein, alpha Interacting Protein (SNCAIP) (AA 1-603) antibodySNCAIP 适用: 人 WB 宿主: 兔 Polyclonal unconjugated
anti-Synuclein, alpha Interacting Protein (SNCAIP) (AA 766-963) antibodySNCAIP 适用: 大鼠 WB, IHC, ICC 宿主: 兔 Polyclonal unconjugated
anti-Synuclein, alpha Interacting Protein (SNCAIP) (AA 593-622), (C-Term) antibodySNCAIP 适用: 人, 小鼠 WB 宿主: 兔 Polyclonal unconjugated
-
- 应用备注
- IHC, WB. A concentration of 10-50 μg,ml is recommended. The optimal concentration should be determined by the end user. Not yet tested in other applications.
- 限制
- 仅限研究用
-
- 状态
- Lyophilized
- 溶解方式
- Reconstitute in 500 μL of sterile water. Centrifuge to remove any insoluble material.
- 注意事项
- Avoid freeze and thaw cycles.
- 储存条件
- 4 °C/-20 °C
- 储存方法
- Maintain the lyophilised/reconstituted antibodies frozen at -20°C for long term storage and refrigerated at 2-8°C for a shorter term. When reconstituting, glycerol (1:1) may be added for an additional stability. Avoid freeze and thaw cycles.
- 有效期
- 12 months
-
- 抗原
- SNCAIP (Synuclein, alpha Interacting Protein (SNCAIP))
- 别名
- Synphilin-1 (SNCAIP 产品)
- 别名
- sncaip antibody, MGC88953 antibody, SNCAIP antibody, LOC100221074 antibody, SYPH1 antibody, Sph1 antibody, Syph1 antibody, 2810407O15Rik antibody, 4933427B05Rik antibody, BB104594 antibody, synuclein alpha interacting protein antibody, synuclein, alpha interacting protein antibody, synuclein, alpha interacting protein (synphilin) antibody, SNCAIP antibody, sncaip antibody, Sncaip antibody
- 背景
- Tissue specificity: Widely expressed, with highest levels in brain, heart and placenta. Defects in SNCAIP are a cause of Parkinson disease (PD). PD is a complex, multifactorial disorder that typically manifests after the age of 50 years, although early-onset cases (before 50 years) are known. PD generally arises as a sporadic condition but is occasionally inherited as a simple mendelian trait. Although sporadic and familial PD are very similar, inherited forms of the disease usually begin at earlier ages and are associated with atypical clinical features. PD is characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. Constructs encoding portions of SNCA and SNCAIP co-transfected in mammalian cells promote cytosolic inclusions resembling the Lewy bodies of Parkinson disease. Coexpression of SNCA, SNCAIP, and PARK2 result in the formation of Lewy body-like ubiquitin-positive cytosolic inclusions. Familial mutations in PARK2 disrupt the ubiquitination of SNCAIP and the formation of the ubiquitin-positive inclusions. These results provide a molecular basis for the ubiquitination of Lewy body-associated proteins and link PARK2 and SNCA in a common pathogenic mechanism through their interaction with SNCAIP.,Neurodegeneration,Alpha-synuclein-interacting protein, SNCAIP
- UniProt
- Q9Y6H5
-
